Hedge Fund Solutions, LLC recently launched an investment research product dedicated to uncovering undervalued publicly traded companies that could have the potential to generate outsized returns due to an activist investor's involvement.
Click here to download a complimentary copy of our latest report, an analysis on Tecumseh Products.
Annual Subscriptions (a minimum of 24 reports/year) are now available. Please message research@hedgerelations.com if you are interested in more information.
*The author has a position in TECUA. This is neither a recommendation to buy or sell any securities. All information provided believed to be reliable and presented for information purposes only.
This forgotten technique developed by Ben Graham can help identify potential bargain stocks. Also, Other Value Strategies, Real Estate, and more. Send feedback to:cheapstocks@verizon.net
Friday, April 24, 2009
Wednesday, April 15, 2009
Despite Recent Market "Run-up", Still plenty of Net/Nets
Markets have recently bounced nicely off their March lows, a situation which might typically create a "rising tide lifts all boats" effect. But while the Russell Microcap Index is up more than 30% from March 9th, there are still plenty of net/nets.
A recent, un-scrubbed screen revealed 325 companies with market caps greater than $5million trading below their net current asset value. While that's more than 100 fewer than the 433 we revealed in our March 2nd post, there's still plenty of opportunity in the land of the lost.
Here are the top 5 Net/Nets by market cap:
Ingram Micro
Ticker: IM
P/E: NA
Market Cap: $2.08 billion
NCAV: $2.247 billion
Mkt Cap/NCAV: .93
Price: $12.85
Cash/Share: $4.7
Skechers
Ticker: SKX
P/E: 6.5
Market Cap: $357 million
NCAV: $394 million
Mkt Cap/NCAV: .91
Price: $7.72
Cash/Share: $2.5
Adaptec
Ticker: ADPT
P/E: 49
Market Cap: $335
NCAV: $370
Mkt Cap/NCAV: .91
Price: $2.75
Cash/Share: $.8
Imation
Ticker: IMN
P/E: 7
Market Cap: $336
NCAV: $399
Mkt Cap/NCAV:.84
Price: $8.91
Cash/Share: $2.6
Facet Biotech
Ticker: FACT
P/E: NA
Market Cap: $240
NCAV: $315
Mkt Cap/NCAV: .76
Price: $9.75
Cash/Share: $16.6
*The author does not have positions in any of the companies mentioned. This is neither a recommendation to buy or sell any securities. All information provided believed to be reliable and presented for information purposes only. The author will not trade any of the securities mentioned (buy, sell, short) for at least two weeks
following the date of this post.
A recent, un-scrubbed screen revealed 325 companies with market caps greater than $5million trading below their net current asset value. While that's more than 100 fewer than the 433 we revealed in our March 2nd post, there's still plenty of opportunity in the land of the lost.
Here are the top 5 Net/Nets by market cap:
Ingram Micro
Ticker: IM
P/E: NA
Market Cap: $2.08 billion
NCAV: $2.247 billion
Mkt Cap/NCAV: .93
Price: $12.85
Cash/Share: $4.7
Skechers
Ticker: SKX
P/E: 6.5
Market Cap: $357 million
NCAV: $394 million
Mkt Cap/NCAV: .91
Price: $7.72
Cash/Share: $2.5
Adaptec
Ticker: ADPT
P/E: 49
Market Cap: $335
NCAV: $370
Mkt Cap/NCAV: .91
Price: $2.75
Cash/Share: $.8
Imation
Ticker: IMN
P/E: 7
Market Cap: $336
NCAV: $399
Mkt Cap/NCAV:.84
Price: $8.91
Cash/Share: $2.6
Facet Biotech
Ticker: FACT
P/E: NA
Market Cap: $240
NCAV: $315
Mkt Cap/NCAV: .76
Price: $9.75
Cash/Share: $16.6
*The author does not have positions in any of the companies mentioned. This is neither a recommendation to buy or sell any securities. All information provided believed to be reliable and presented for information purposes only. The author will not trade any of the securities mentioned (buy, sell, short) for at least two weeks
following the date of this post.
Thursday, April 09, 2009
Catalyst Investment Research- Consolidated Tomoka Land
Hedge Fund Solutions, LLC recently launched an investment research product dedicated to uncovering undervalued publicly traded companies that could have the potential to generate outsized returns due to an activist investor's involvement.
Click here to download a complimentary copy of our latest report, an analysis on Consolidated Tomoka Land.
Annual Subscriptions (a minimum of 24 reports/year) are now available. Please message research@hedgerelations.com if you are interested in more information.
*The author does not have positions in any of the companies mentioned. This is neither a recommendation to buy or sell any securities. All information provided believed to be reliable and presented for information purposes only.
Click here to download a complimentary copy of our latest report, an analysis on Consolidated Tomoka Land.
Annual Subscriptions (a minimum of 24 reports/year) are now available. Please message research@hedgerelations.com if you are interested in more information.
*The author does not have positions in any of the companies mentioned. This is neither a recommendation to buy or sell any securities. All information provided believed to be reliable and presented for information purposes only.
Wednesday, April 08, 2009
Rest In Peace, James G Boswell II
James G. Boswell II, a major focus of the great book on the JG Boswell farming empire entitled "The King of California: J.G. Boswell and the Making of a Secret American Empire" passed away last Friday at age 86. Here's the obituary from the LA Times (thanks to Cheap Stocks reader Scott Hall for this link).
Boswell presided over JG Boswell, Co (Ticker:BWEL), one of the most interesting quasi-publicly traded companies that most investors have never heard of, as chairman, president and CEO from 1952 until 1984. He was still serving on the board of directors at the time of his death.
For more on the company, see our most recent BWEL post.
*The author has a position in JG Boswell. This is neither a recommendation to buy or sell any securities. All information provided believed to be reliable and presented for information purposes only.
Boswell presided over JG Boswell, Co (Ticker:BWEL), one of the most interesting quasi-publicly traded companies that most investors have never heard of, as chairman, president and CEO from 1952 until 1984. He was still serving on the board of directors at the time of his death.
For more on the company, see our most recent BWEL post.
*The author has a position in JG Boswell. This is neither a recommendation to buy or sell any securities. All information provided believed to be reliable and presented for information purposes only.
Subscribe to:
Posts (Atom)